Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500224 | 0.81 | MAPT (0.38) | HCAR2HPGDTSHR | |
| Hydrochloric Acid SCHEMBL3500648 | 0.79 | MAPT (0.37) | HCAR2HPGDTSHR | |
| SCHEMBL1206509 | 0.78 | HPGD (0.56) | HCAR2COMTHPGDTSHRCCNA2 | |
| Hydrochloric Acid SCHEMBL3501057 | 0.76 | HPGD (0.33) | HPGDTSHR | |
| SCHEMBL2581322 | 0.75 | HCAR2 (0.44) | HCAR2COMTHPGDTSHRCCNA2 | |
| Hydrochloric Acid SCHEMBL3498403 | 0.74 | HPGD (0.65) | HCAR2COMTHPGDTSHR | |
| SCHEMBL14037797 | 0.73 | HCAR2 (0.47) | HCAR2COMTHPGDTSHRCCNA2 | |
| SCHEMBL5086281 | 0.72 | HCAR2 (0.42) | HCAR2COMTHPGDTSHRCCNA2 | |
| SCHEMBL12930817 | 0.68 | HPGD (0.55) | HPGDTSHR | |
| SCHEMBL174227 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2121619-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC Immune S.A. (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | HCAR2 700/4885COMT 4011/4885HPGD 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.